New cell therapy YTB323 targets MS that breaks through strongest drugs
NCT ID NCT06617793
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests an experimental cell therapy called YTB323 in about 28 people with relapsing multiple sclerosis whose disease is still active despite taking strong medications. The goal is to see if YTB323 is safe and can control the disease. Participants receive a single dose, and researchers monitor side effects, disability changes, and how the therapy behaves in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGDarlinghurst, New South Wales, 2010, Australia
-
Novartis Investigative Site
RECRUITINGMelbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
RECRUITINGMontpellier, 34090, France
-
Novartis Investigative Site
RECRUITINGNancy, 54035, France
-
Novartis Investigative Site
RECRUITINGRennes, 35033, France
-
Novartis Investigative Site
RECRUITINGBochum, 44791, Germany
-
Novartis Investigative Site
RECRUITINGEssen, 45147, Germany
-
Novartis Investigative Site
RECRUITINGMainz, 55131, Germany
-
Novartis Investigative Site
RECRUITINGUlm, 89081, Germany
-
Novartis Investigative Site
RECRUITINGGenova, GE, 16132, Italy
-
Novartis Investigative Site
RECRUITINGMilan, MI, 20132, Italy
-
Novartis Investigative Site
RECRUITINGBarcelona, 08035, Spain
-
Novartis Investigative Site
RECRUITINGCórdoba, 14004, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28034, Spain
-
Novartis Investigative Site
RECRUITINGValencia, 46026, Spain
-
Novartis Investigative Site
RECRUITINGBern, 3010, Switzerland
-
Novartis Investigative Site
RECRUITINGLausanne, 1011, Switzerland
-
Novartis Investigative Site
RECRUITINGZurich, 8091, Switzerland